{"id":790949,"date":"2024-11-26T16:18:30","date_gmt":"2024-11-26T21:18:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/"},"modified":"2024-11-26T16:18:30","modified_gmt":"2024-11-26T21:18:30","slug":"89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/","title":{"rendered":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) &#8212; 89bio, Inc. (the \u201cCompany\u201d or \u201c89bio\u201d) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company\u2019s Management will participate in a fireside chat at the 7<sup>th<\/sup> Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.<\/p>\n<p>The webcast of the fireside chat will be accessible in the investor section of\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WvV27Pk7S4U4ylFKJ3k8WNi80Yl_pKbBZ48NdeY1uVtO8shxEqSN_4PgFIAm-ea_XsbA-m18jXh56eWVXrdHixM37y_Os-omSdP__w16FVqHRpm6gA8eT-0P3QqrX82YwjWZOUdzioH8HB4gtkKFc8w2d4uf9SxRDA57WwG-QULONyyH75nPBKES8DY7ThkCyN32i8o8h8A1qWq3aE-7eSyu62wzqa3332bFwtRI2pFuzujHPFh2rlzvTJpRbbb9xnFHGcWJltlesJuJQNeAEK5tGzMRF_jsJgvQJ7QLaNw=\" rel=\"nofollow\" target=\"_blank\">89bio\u2019s website<\/a>. A replay of the webcast will be available for approximately 30 days following the conference.<\/p>\n<p>\n        <strong>About 89bio<\/strong><br \/>\n        <br \/>89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dsr6oJRzrWvaTBbwf6XjIg1uBW2ewirYVuitWJ66bEzdyiO-tNHTqftT0WutOmwQM81_fQkkRYngk8JfFeu10w==\" rel=\"nofollow\" target=\"_blank\">www.89bio.com<\/a> or follow the company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O6i-sg_NzVEm02JQk-ZZ-lrv_qDDZTYgmqigX1xoY_BrMTobqdC7p1h_6kShTQtBZcPvgZ8RyYf0WvVuOjiQy4DPb4kARezEE0Ocd-wMMcQ=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:\u00a0<\/strong><br \/>\n        <br \/>Annie Chang\u00a0<br \/>89bio, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SHbcdSgPJ-ec73_DUzMczt4ajlqoocRJTS2BKry73Q9WDqAQ5IuZbDB_1ED2hIjt8qrJjmtks6dtNzeK-aIchSaF4PIanUisJPLAtiyeCCX4QZsRtpOEhlwmP38VqIQQ5S7gYo8mw5uIXf52GxLb_bFzp6dcQOVmjZgM_CYysAGf6lFUuhQQI-yJNL2eUYQ_JZde6JwXMgPjUy9a4IbqxAvwCws3uUwaXxtaPJU0yMnmb2-deSiBkUzCbCU1zXAuPxNCqk7Ngm8kIJA69qY2yg==\" rel=\"nofollow\" target=\"_blank\">investors@89bio.com<\/a><\/p>\n<p>PJ Kelleher<br \/>LifeSci Advisors, LLC<br \/>617-430-7579<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HifOqIg3AO_AIPGpKH609bJ3IT3ghlK1FUjOsvjpwfaIcY_vZ1YmTu1PjTneFA8VMScFgQutHblODBiwt17WPrm6GDM5J5M40kysqhZKsMzTsOUEtg9gs-Zs5qpbEjSA\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:\u00a0<\/strong><br \/>\n        <br \/>Sheryl Seapy<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BtZL30J4QsQTe87o_-lVUWQ5Ptdg_SNtnMjPoQ7kfMIRtPX7-qMrEpXHisRz7gutspUW6RbebN1RLzfi1dUh3EAmqj5QxAepmNnnCXzLB9c=\" rel=\"nofollow\" target=\"_blank\">sseapy@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjM5OGNlM2MtODAzNC00YjQwLTk4MWYtMTdhMzc4ZDYxOThlLTEyMDE1OTM=\/tiny\/89bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) &#8212; 89bio, Inc. (the \u201cCompany\u201d or \u201c89bio\u201d) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company\u2019s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of\u00a089bio\u2019s website. A replay of the webcast will be available for approximately 30 days following the conference. About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;89bio to Participate in the 7th Annual Evercore HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-790949","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) &#8212; 89bio, Inc. (the \u201cCompany\u201d or \u201c89bio\u201d) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company\u2019s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of\u00a089bio\u2019s website. A replay of the webcast will be available for approximately 30 days following the conference. About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with &hellip; Continue reading &quot;89bio to Participate in the 7th Annual Evercore HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-26T21:18:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"89bio to Participate in the 7th Annual Evercore HealthCONx Conference\",\"datePublished\":\"2024-11-26T21:18:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/\"},\"wordCount\":232,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/\",\"name\":\"89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\",\"datePublished\":\"2024-11-26T21:18:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"89bio to Participate in the 7th Annual Evercore HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk","og_description":"SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) &#8212; 89bio, Inc. (the \u201cCompany\u201d or \u201c89bio\u201d) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company\u2019s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of\u00a089bio\u2019s website. A replay of the webcast will be available for approximately 30 days following the conference. About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with &hellip; Continue reading \"89bio to Participate in the 7th Annual Evercore HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-26T21:18:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference","datePublished":"2024-11-26T21:18:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/"},"wordCount":232,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/","name":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=","datePublished":"2024-11-26T21:18:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDQ3MiM2NjEyMjk3IzIxOTAwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/89bio-to-participate-in-the-7th-annual-evercore-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=790949"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790949\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=790949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=790949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=790949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}